BR112017020434A2 - polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2 - Google Patents
polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2Info
- Publication number
- BR112017020434A2 BR112017020434A2 BR112017020434A BR112017020434A BR112017020434A2 BR 112017020434 A2 BR112017020434 A2 BR 112017020434A2 BR 112017020434 A BR112017020434 A BR 112017020434A BR 112017020434 A BR112017020434 A BR 112017020434A BR 112017020434 A2 BR112017020434 A2 BR 112017020434A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion polypeptide
- induce
- local
- cell response
- fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166179 | 2015-05-04 | ||
| EP15167917 | 2015-05-18 | ||
| EP15002702 | 2015-09-17 | ||
| EP15192870 | 2015-11-04 | ||
| EP16150705 | 2016-01-11 | ||
| EP16000862 | 2016-04-15 | ||
| PCT/EP2016/060041 WO2016177802A1 (en) | 2015-05-04 | 2016-05-04 | Anti-cancer fusion polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017020434A2 true BR112017020434A2 (pt) | 2018-06-26 |
Family
ID=55948826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020434A BR112017020434A2 (pt) | 2015-05-04 | 2016-05-04 | polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2 |
Country Status (13)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| PH12017501583B1 (en) | 2015-05-04 | 2023-01-20 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for cd137 |
| DK3298030T5 (en) | 2015-05-18 | 2024-10-07 | Pieris Pharmaceuticals Gmbh | Anti-cancerfusionspolypeptid |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| JP7085709B2 (ja) | 2016-06-20 | 2022-06-17 | エフ-スター セラピューティクス リミテッド | Pd-l1及びlag-3に結合する結合分子 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| CA3047070A1 (en) * | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| CA3082297A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| CA3086098A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| MX2020010015A (es) | 2018-03-26 | 2021-01-15 | 4Sc Ag | Combinacion que comprende inhibidor de hdac y agonista de cd137 para la terapia del cancer. |
| CR20200459A (es) * | 2018-04-13 | 2020-11-11 | Hoffmann La Roche | Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| RS64343B9 (sr) * | 2018-07-31 | 2023-11-30 | Pieris Pharmaceuticals Gmbh | Novi fuzioni protein specifičan za cd137 i pd-l1 |
| AU2019328632A1 (en) * | 2018-08-27 | 2021-03-25 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof |
| JP7476219B2 (ja) | 2019-02-26 | 2024-04-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Cd137およびgpc3に特異的な新規融合タンパク質 |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| CN113677403B (zh) * | 2019-04-12 | 2024-12-27 | 豪夫迈·罗氏有限公司 | 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子 |
| CN118638240A (zh) * | 2019-07-26 | 2024-09-13 | 柳韩洋行 | 抗her2/抗4-1bb双特异性抗体及其用途 |
| AU2020379176A1 (en) * | 2019-11-04 | 2022-06-09 | Pieris Pharmaceuticals Gmbh | HER2/4-1BB bispecific fusion proteins for the treatment of cancer |
| KR20220145859A (ko) * | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| WO2022029496A1 (en) * | 2020-08-07 | 2022-02-10 | Eutilex Co., Ltd. | Anti-her2 / anti-4-1bb bispecific antibodies and uses thereof |
| EP4213946A1 (en) | 2020-09-18 | 2023-07-26 | Pieris Pharmaceuticals GmbH | Biomarker methods and uses |
| JP7875865B2 (ja) * | 2021-01-25 | 2026-06-18 | ユーハン・コーポレイション | 抗4-1bb/抗her2二重特異性抗体の精製方法 |
| CN117355319A (zh) | 2021-03-23 | 2024-01-05 | 皮里斯制药有限责任公司 | 用于癌症治疗的her2/4-1bb双特异性融合蛋白 |
| WO2022200478A1 (en) | 2021-03-24 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor |
| IL307744A (en) | 2021-04-22 | 2023-12-01 | Astellas Pharma Inc | Anti-CLDN4/anti-CD137 bispecific antibody |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| KR20250075621A (ko) | 2022-09-20 | 2025-05-28 | 바이오세우스 인크. | 항체 및 종양 저항에서의 이의 용도 |
| CN119997975A (zh) | 2022-10-19 | 2025-05-13 | 安斯泰来制药株式会社 | 抗cldn4-抗cd137双特异性抗体通过与pd-1信号抑制剂的组合在癌症治疗中的应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| EP1012275A1 (en) | 1997-01-31 | 2000-06-28 | University Of Rochester | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
| US6020163A (en) | 1997-08-06 | 2000-02-01 | Zymogenetics, Inc. | Lipocalin homolog |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US20140080177A1 (en) | 1997-09-26 | 2014-03-20 | Pieris Ag | Anticalins |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ.ホフマン−ラ ロシュ アーゲー | 慢性C型肝炎の処置のためのPeg−INF−アルファ及びリバビリンの使用 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| CA2343917A1 (en) | 1998-10-19 | 2000-04-27 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| DE602007009995D1 (de) * | 2006-08-01 | 2010-12-02 | Pieris Ag | Muteine von tearlipocalin und verfahren zu deren gewinnung |
| EP2225268B1 (en) | 2007-10-19 | 2012-08-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| US20090226435A1 (en) | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| US8420051B2 (en) | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| EP2401296A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
| EA201190273A1 (ru) | 2009-05-28 | 2012-12-28 | Глаксо Груп Лимитед | Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз |
| BR112012002709A2 (pt) | 2009-08-05 | 2019-04-30 | Pieris Ag | formulações de liberação controlada de muteínas de lipocalina |
| BR112012013662B1 (pt) * | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| US8993524B2 (en) * | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| AU2011290751B2 (en) | 2010-08-16 | 2015-08-13 | Pieris Ag | Binding proteins for Hepcidin |
| CA2817779C (en) | 2010-11-15 | 2019-02-19 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| US9221885B2 (en) | 2010-12-02 | 2015-12-29 | Pieris Ag | Muteins of human lipocalin 2 with affinity for CTLA-4 |
| PL3489254T3 (pl) * | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| HK1245154A1 (zh) * | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| WO2016113203A1 (en) | 2015-01-12 | 2016-07-21 | Pieris Ag | Engineered t cells and uses therefor |
| SG11201705278QA (en) | 2015-01-28 | 2017-07-28 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| EP3259282A1 (en) | 2015-02-18 | 2017-12-27 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| PH12017501583B1 (en) | 2015-05-04 | 2023-01-20 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for cd137 |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-04 RU RU2017135596A patent/RU2727165C2/ru active
- 2016-05-04 JP JP2017557310A patent/JP6783797B2/ja not_active Expired - Fee Related
- 2016-05-04 MX MX2017014083A patent/MX2017014083A/es unknown
- 2016-05-04 AU AU2016258977A patent/AU2016258977C1/en not_active Ceased
- 2016-05-04 CN CN202111366682.4A patent/CN114316067A/zh active Pending
- 2016-05-04 US US15/571,561 patent/US10865250B2/en active Active
- 2016-05-04 KR KR1020177034820A patent/KR20170138574A/ko active Pending
- 2016-05-04 EP EP24151494.2A patent/EP4378962A3/en not_active Withdrawn
- 2016-05-04 WO PCT/EP2016/060041 patent/WO2016177802A1/en not_active Ceased
- 2016-05-04 SG SG11201708334RA patent/SG11201708334RA/en unknown
- 2016-05-04 BR BR112017020434A patent/BR112017020434A2/pt not_active Application Discontinuation
- 2016-05-04 EP EP16721154.9A patent/EP3292148B1/en active Active
- 2016-05-04 CA CA2980840A patent/CA2980840A1/en active Pending
- 2016-05-04 CN CN201680025273.9A patent/CN107636014B/zh not_active Expired - Fee Related
-
2017
- 2017-09-01 ZA ZA2017/05961A patent/ZA201705961B/en unknown
-
2020
- 2020-11-12 US US17/096,750 patent/US20210198380A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1249526A1 (en) | 2018-11-02 |
| SG11201708334RA (en) | 2017-11-29 |
| CN107636014B (zh) | 2021-12-07 |
| US10865250B2 (en) | 2020-12-15 |
| EP4378962A3 (en) | 2024-07-31 |
| CA2980840A1 (en) | 2016-11-10 |
| ZA201705961B (en) | 2023-12-20 |
| US20210198380A1 (en) | 2021-07-01 |
| EP4378962A2 (en) | 2024-06-05 |
| JP2018515085A (ja) | 2018-06-14 |
| JP6783797B2 (ja) | 2020-11-11 |
| CN107636014A (zh) | 2018-01-26 |
| KR20170138574A (ko) | 2017-12-15 |
| US20190010248A1 (en) | 2019-01-10 |
| AU2016258977C1 (en) | 2022-07-14 |
| RU2017135596A (ru) | 2019-06-04 |
| CN114316067A (zh) | 2022-04-12 |
| AU2016258977A1 (en) | 2017-11-30 |
| MX2017014083A (es) | 2018-11-09 |
| RU2017135596A3 (cg-RX-API-DMAC7.html) | 2019-09-16 |
| EP3292148A1 (en) | 2018-03-14 |
| RU2727165C2 (ru) | 2020-07-21 |
| EP3292148B1 (en) | 2024-01-24 |
| AU2016258977B2 (en) | 2022-03-17 |
| WO2016177802A1 (en) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
| MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
| CL2021002094A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153) | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112018000366A2 (pt) | polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão | |
| BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| MX2019006727A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| BR112015017800A2 (pt) | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| BR112018068391A2 (pt) | sistema e métodos para produzir uma proteína, célula inoculada, construção de rna para expressar a replicase de alfavírus e dna | |
| BR112022011854A2 (pt) | Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| MX391015B (es) | Composiciones de nanoparticulas y usos de las mismas | |
| BR112017015773A2 (pt) | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo | |
| NZ736560A (en) | Proteins specific for cd137 | |
| WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
| BR112014019459A8 (pt) | Proteínas de ligação à cdim e usos das mesmas | |
| BR112015018203A2 (pt) | Anti-corpos biespecíficos anti-tnf-anti-il-17 | |
| NZ759601A (en) | Aggrecan binding immunoglobulins | |
| SA518391728B1 (ar) | بولي بيبتيدات ثنائية المستوقع المضادة لإشارة ونت في خلايا ورم | |
| BR112022008321A2 (pt) | Polipeptídeos isolados, polipeptídeo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para tratar câncer, para tratar uma doença neurológica ou neurodegenerativa, para repolarizar células supressoras, para repolarizar macrófagos de tumor e para ativar células mieloides em um sujeito e composições farmacêuticas | |
| BR112016023025A2 (pt) | direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |